CD38 and Miyoshi myopathy: Another study by Mei H et al. reported the construction of a humanized bispecific BM38-CAR that targets BCMA and CD38, which revealed that the bispecific CAR-T cells had more potent cytotoxicity against heterogeneous MM cells compared to CAR-T cells expressing only BCMA or CD38 [85].